![]() Swedish Orphan Biovitrum Swedish Orphan Biovitrum (Sobi) is an integrated biotechnology company that researches, develops, manufactures, and sells treatments in the areas of hematology, immunology, and specialty care. | |||||
Founding Date | Founding Date 2003 | Founding Date 1946 | Founding Date 1953 | Founding Date 2010 | Founding Date 1929 |
Type | Type Private | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Gentilly, FR HQ Anderlecht, BE Espoo, FI Ciudad De México, MX Nouasseur, MA Warszawa, PL Lisboa, PT see more | Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more | |||
Employees | Employees 3,4721% increase | Employees 4,590 | Employees 1,5741% increase | Employees 1,895 | Employees 5,358 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 11.1 b | Valuation ($) 10.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) Kč2.3b (FY, 2021) | Revenue (est.) N/A | Revenue (est.) €310m (FY, 2018) | Revenue (est.) kr28.2b (FY, 2025) | Revenue (est.) €3.7b (FY, 2025) |
Cost of goods | Cost of goods Kč807.2m (FY, 2021) | Cost of goods N/A | Cost of goods N/A | Cost of goods kr6.2b (FY, 2025) | Cost of goods €659.1m (FY, 2025) |
Gross profit | Gross profit Kč1.5b (FY, 2021) | Gross profit N/A | Gross profit N/A | Gross profit kr22b (FY, 2025) | Gross profit €3.3b (FY, 2025) |
Net income | Net income (Kč831.2m) (FY, 2021) | Net income N/A | Net income N/A | Net income kr476m (FY, 2025) | Net income €445.1m (FY, 2025) |
Operating ⚠ | |||||
Countries | Countries 35 (Apr, 2023) | Countries N/A | Countries 120 (Dec, 2019) | Countries N/A | Countries N/A |

Biocodex is a pharmaceutical company that specializes in the development of drugs.
View company
Swedish Orphan Biovitrum (Sobi) is an integrated biotechnology company that researches, develops, manufactures, and sells treatments in the areas of hematology, immunology, and specialty care.
View company